OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus ... MarketWatch (press release) Patients are randomized into two arms: one arm receives bevacizumab 15 mg/kg IV on day 1 and then every three weeks; the second arm receives bevacizumab plus fosbretabulin tromethamine 60 mg/m2 IV on day 1 and then every three weeks. Patients are ... |
Monday, August 6, 2012
OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus ... - MarketWatch (press release)
deeshu-tatum.blogspot.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment